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LETTER TO THE EDITOR
An Updated Meta-
Analysis of Randomized
Controlled Trials
Comparing Irinotecan/
Platinum with
Etoposide/Platinum in
Patients with Previously
Untreated Extensive-
Stage Small Cell Lung
Cancer
To the Editor:
The cornerstone of therapy for ex-
tensive-stage small cell lung cancer (E-
SCLC) has been etoposide combined with
platinum (EP) over the past two decades.
Irinotecan plus platinum (IP) has also been
demonstrated effective, while the superi-
ority of IP over EP as first-line therapy for
E-SCLC remains controversial. In the is-
sue of May 2010, Jiang et al.1 reported a
meta-analysis which demonstrated the su-
periority of IP versus EP in the first-line
treatment of patients with E-SCLC. We
have updated the data by two new studies
published after the literature search com-
pletion date of the above meta-analysis.
Among them, one was a randomized
phase III study2 published in March 2010
and the other was a German phase III trial3
published in January 2011. In fact, the
German phase III trial3 was just the final
outcome of a phase II trial4 published in
2006 which was analyzed in the meta-
analysis by Jiang et al.1 Using the same
method as Jiang et al.1 did for meta-anal-
ysis, we complemented it including the
latest data.
At last, data of seven trials were
analyzed. The baseline characteristics of
each trial are presented in Table 1. A
total of 2027 patients with E-SCLC
were available for the meta-analysis.
Statistical analyses were calculated us-
ing STATA 10.1 package (StataCorp,
College Station, TX).
OVERALL RESPONSE RATE
The pooled relative risk (RR) for
overall response rate (ORR) showed that
there was no significant difference be-
tween two regimens (RR  1.04, 95%
confidence interval [CI]: 0.95–1.13, p 
0.378). The heterogeneity test did not
yield a significant result (p  0.190),
and the pooled RR for ORR was calcu-
lated using fixed-effects model. The
subgroup meta-analysis and sensitivity
analysis of the trials using cisplatin also
showed no significant difference be-
tween two regimens (Figure 1).
OVERALL SURVIVAL
The pooled hazard ratio (HR) for
overall survival (OS) showed that IP
was superior to EP (HR 0.81, 95% CI:
0.71–0.93, p  0.003). There was no
significant heterogeneity (p  0.081),
and the pooled HR for OS was calcu-
lated using fixed-effects model. The
subgroup meta-analysis and sensitivity
analysis of the trials using cisplatin also
showed an advantage of IP (Figure 1).
PROGRESSION-FREE SURVIVAL
The pooled HR for progression-
free survival failed to display a differ-
ence between two regimens (HR 
0.90, 95% CI: 0.76–1.07, p  0.227).
There was significant heterogeneity
(p  0.012), and the pooled HR for
progression-free survival was calculated
using random-effects model. The sub-
group meta-analysis and sensitivity
analysis of the trials using cisplatin also
showed no significant difference be-
tween two regimens (Figure 1).
TOXICITIES
Compared with EP, IP led to less
grade 3 to 4 neutropenia (odds ratio
[OR]  0.18, 95% CI: 0.10–0.34, p 
0.00001), anemia (OR  0.58, 95%CI:
0.44–0.78, p  0.0003), and thrombo-
cytopenia (OR  0.31, 95% CI: 0.19–
0.53, p  0.0001) while more grade 3 to
4 vomiting (OR  1.78, 95% CI: 1.26–
2.51, p  0.001) and diarrhea (OR 
9.81, 95% CI: 4.37–22.02, p 0.00001)
(Table 2).
The present meta-analysis failed
to display a difference in ORR between
two regimens, which was different from
results of Jiang et al.1 Nevertheless, our
results demonstrated a significant supe-
riority in OS for IP compared with EP,
which was in line with the meta-analysis
by Jiang et al.1 and another one by Lima
et al.5 In conclusion, these results dem-
onstrated significant OS benefit of IP
over EP with a different toxicity profile.
Consequently, IP regimen should be
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TABLE 1. Characteristics of the Seven Trials Included in the Meta-Analysis
Author
Quality
(Scores) Regimens
Enrolled
Patients
Median
Age
PS
0–1 (%)
Noda
(2002)
2 I: 60 mg/m2 d1, 8, 15DDP: 60 mg/m2 d1, 28 d/cycle 77 63 92
E: 100 mg/m2 d1–3DDP: 80 mg/m2 d1, 21 d/cycle 77 63 87
Hanna
(2006)
2 I: 65 mg/m2 d1, 8DDP: 30 mg/m2 d1, 8, 21 d/cycle 221 63 92
E: 120 mg/m2 d1–3DDP: 60 mg/m2 d1, 21 d/cycle 110 62 88
Pan
(2006)
4 I: 80 mg/m2 d1, 8, 15DDP: 27 mg/m2 d1–3, 28 d/cycle 30 54 100
E: 120 mg/m2 d1–3DDP: 27 mg/m2 d1–3, 21 d/cycle 31 51 100
Hermes
(2008)
2 I: 65 mg/m2 d1, 8  CBP: AUC  4 d1, 21 d/cycle 105 67 53
E*: 120 mg/m2 d1–5  CBP: AUC  4 d1, 21 d/cycle 104 68 52
Lara
(2009)
2 I: 60 mg/m2 d1, 8, 15DDP: 60 mg/m2 d1, 28 d/cycle 324 62 100
E: 100 mg/m2 d1–3DDP: 80 mg/m2 d1, 21 d/cycle 327 63 100
Zatloukal
(2010)
2 I: 65 mg/m2 d1, 8DDP: 80 mg/m2 d1, 21 d/cycle 202 60 99
E: 100 mg/m2 d1–3DDP: 80 mg/m2 d1, 21 d/cycle 203 61 100
Schmittel
(2011)
3 I: 50 mg/m2 d1, 8, 15  CBP: AUC  5 d1, 28 d/cycle 106 60 80
E: 140 mg/m2 d1–3  CBP: AUC  5 d1, 21 d/cycle 110 63 80
I, irinotecan; E, etoposide; E*, oral etoposide; DDP, cisplatin; CBP, carboplatin; AUC, area under (the plasma
concentration time) curve; PS, performance status by Zubrod-ECOG-WHO; ECOG, Eastern Cooperative Oncology
Group; WHO, World Health Organization.
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strongly considered as a standard first-
line treatment for patients with E-SCLC.
At the same time, we recognized
that significant heterogeneity was found
between the enrolled studies. The rea-
sons for heterogeneity may be the phar-
macogenomic differences between study
populations and race, as well as differ-
ences in the studied treatment regimens
and their pharmacokinetics. In the future,
an analysis of individual patient data is
awaited to confirm our findings.
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FIGURE 1. The pooled relative risk for overall response rate and the pooled haz-
ard ratio (HR) for overall survival and progression-free survival.
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TABLE 2. Grade 3 to 4 Toxicities of Irinotecan/Platinum vs. Etoposide/Platinum
in E-SCLC
Grade 3 to 4 Toxicities No. of Patients OR 95% CI p I2 (%)
Leukopenia 1696 0.42 0.26–0.68 0.0004 68.6
Neutropenia 1602 0.18 0.10–0.34 0.00001 81.0
Anemia 2027 0.58 0.44–0.78 0.0003 0
Thrombocytopenia 2027 0.31 0.19–0.53 0.0001 65.9
Vomiting 1818 1.78 1.26–2.51 0.001 11.5
Diarrhea 2027 9.81 4.37–22.02 0.00001 46.9
An OR 1 favors irinotecan/platinum regimen, whereas an OR 1 favors etoposide/platinum regimen.
E-SCLC, extensive-stage small cell lung cancer; OR, odds ratio; CI, confidence interval.
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